Cardium Therapeutics Inc Stock Nyse
Equities
US1419161062
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2022 | Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt | CI |
2021 | Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 | CI |
Financials (USD)
Sales 2019 | - | Sales 2020 | - | Capitalization | 551K |
---|---|---|---|---|---|
Net income 2019 | - | Net income 2020 | - | EV / Sales 2019 | - |
Net Debt 2019 | 1.12M | Net Debt 2020 | 874K | EV / Sales 2020 | - |
P/E ratio 2019 |
3.09
x | P/E ratio 2020 |
-1.77
x | Employees | - |
Yield 2019 * |
-
| Yield 2020 |
-
| Free-Float | 93.84% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 70 | 03-12-21 | |
James Grainer
CHM | Chairman | 69 | 20-05-21 |
Lois Chandler
COO | Chief Operating Officer | - | 10-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 70 | 03-12-21 | |
James Grainer
CHM | Chairman | 69 | 20-05-21 |
Ronald Shebuski
CTO | Chief Tech/Sci/R&D Officer | 71 | 20-05-21 |
1st Jan change | Capi. | |
---|---|---|
+30.50% | 49.46B | |
+1.22% | 42.58B | |
+49.17% | 42.49B | |
-5.26% | 29.09B | |
+12.78% | 26.61B | |
-23.79% | 18.64B | |
+7.43% | 13.16B | |
+31.44% | 12.55B | |
+23.07% | 12.1B |